Evolus (NASDAQ:EOLS) Posts Earnings Results

Evolus (NASDAQ:EOLS) posted its quarterly earnings data on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.13), FiscalAI reports. The firm had revenue of $77.95 million during the quarter, compared to analyst estimates of $77.58 million.

Here are the key takeaways from Evolus’ conference call:

• Third-quarter revenue rose 13% to $78 million, including $70.1 million in toxin revenue and $7.9 million in HA revenue. Adjusted EBITDA was positive for the fourth consecutive quarter at $1.2 million; year-to-date adjusted EBITDA improved to $6.4 million from a loss of $16.5 million a year earlier.
• Evolus reaffirmed full-year revenue guidance of $330 million–$337 million and adjusted gross margin guidance of 67%–67.5%, while lowering its non-GAAP operating expense outlook to $210 million–$213 million. It also maintained its low- to mid-single-digit adjusted EBITDA margin outlook for 2026 and 2028 targets of $450 million–$500 million in revenue and 13%–15% adjusted EBITDA margins.
• Commercial traction broadened: the company added more than 500 purchasing accounts, bringing its cumulative customer base above 19,000, while more than 4,500 customers have purchased Evolysse. Evolus Rewards membership increased 23% year over year to more than 1.6 million, and the company said about 70% of existing patients return for repeat treatment.
• The company expects FDA approval of Evolysse Sculpt in the fourth quarter of 2026 and anticipates submitting the Lips PMA before year-end, with a launch expected in early 2028. Profhilo is a longer-term U.S. opportunity with approval anticipated around 2030; the hair-growth asset remains an early-stage option subject to human data.
• The FDA issued an untitled letter concerning a single Jeuveau social-media post. Management said the post was removed, the concern would be addressed, and the letter would not affect Jeuveau promotion or the business.

Evolus Stock Up 1.4%

Shares of NASDAQ EOLS traded up $0.10 during trading on Wednesday, hitting $7.47. 830,278 shares of the company traded hands, compared to its average volume of 698,632. Evolus has a 1 year low of $3.86 and a 1 year high of $9.31. The company has a 50-day moving average price of $7.89 and a 200-day moving average price of $6.29. The firm has a market capitalization of $493.39 million, a P/E ratio of -14.37 and a beta of 1.38.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 105,108 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the transaction, the insider directly owned 499,592 shares of the company’s stock, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on EOLS shares. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Tuesday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.